spec sheet11 rows
Adafenoxate is a little-known nootropic that is essentially the adamantane version of meclofenoxate (centrophenoxine). Like its parent it pairs an ester carrier with DMAE (dimethylaminoethanol), a choline-related molecule tied to acetylcholine and to membrane maintenance, but swaps the parent's chlorophenoxyacetic acid for a bulky adamantane group. Almost all of what is known comes from a cluster of Bulgarian rodent studies from the late 1980s and early 1990s, where it behaved like a cholinergic, monoamine-modulating, memory-protective agent. There is essentially no modern or human data, so it is a research curiosity rather than an established supplement.
- Adamantane twist on the classic meclofenoxate/DMAE nootropic
- Protected memory against a cholinergic-blockade challenge in rodents
- Broad monoamine and cholinergic modulation in animal work
- Showed anti-anxiety and mild blood-flow effects in early studies
Mechanism
Adafenoxate is a structural analog of meclofenoxate, and meclofenoxate itself is a carrier ester of DMAE, a dimethylaminoethanol species related to and to the upkeep of neuronal membranes [1][7]. In aged-rat brains, adafenoxate and meclofenoxate both raised in the and striatum, and adafenoxate additionally shifted noradrenaline and in a region-specific way, suggesting it nudges several monoamine systems at once rather than acting on a single transmitter [1][2]. In synaptosome (nerve-terminal) preparations it inhibited the reuptake of , noradrenaline, and , and was actually the more potent uptake inhibitor of the nootropics tested, without much selectivity between systems [5].
On the cholinergic side, which is central to memory, adafenoxate and meclofenoxate reduced the number of receptors while increasing their binding affinity, a pattern the authors read as an overall increase in the functional capacity of the brain's cholinergic system [4]. Behaviorally, it protected against scopolamine-induced amnesia (scopolamine blocks receptors and is a standard way to induce memory deficits), placing it among classic anti-amnestic nootropics [3]. It also showed anti-anxiety effects in a conflict test and a modest relaxing action on arterial smooth muscle, hinting at a cerebral-blood-flow component to its profile [6][8]. Separately, a decrease in hippocampal 5-HT1 binding sites after chronic dosing was proposed as one more contributor to its cognitive effects [7].
The honest bottom line is that this is a thinly characterized compound. The mechanistic picture is assembled from a handful of old animal studies by largely one research group, its antioxidant/membrane story is inferred from meclofenoxate rather than directly proven for adafenoxate, and there is no controlled human evidence.
receptor fingerprint
Brain receptorslowers receptor number, raises affinity (net cholinergic boost)
Monoamine reuptake (DA / NA / )non-selective uptake inhibition
Scopolamine-induced amnesiaprotective (anti-amnestic)
Cerebral/arterial smooth musclemild relaxation / anti-vasoconstriction
Safetyrisks and cautions, not medical advice
Adafenoxate has essentially no human safety data and only sparse decades-old animal work, so treat it as experimental. By analogy to meclofenoxate/DMAE-type compounds, plausible effects include cholinergic overstimulation (headache, jaw tension, irritability, sleep disruption) if overdone, but this is inference, not established. Its monoamine-reuptake-inhibiting action means caution is warranted with other serotonergic or catecholaminergic drugs. DMAE-class agents are generally avoided in pregnancy for lack of data. Not a validated treatment for any condition.
Subjective profileweighing the evidence above
Interesting as a footnote to centrophenoxine, but the whole case is thirty-year-old rodent work with zero human data. Anyone actually wanting a DMAE-type nootropic should take meclofenoxate, which at least has been used in people.
Resources
This entry is here for reference.
Research
- 1987first citedEffects of the nootropic agents adafenoxate, meclofenoxate and the acetylcholine precursor citi…
- 1988most active year3 papers
- 1994most recentBiogenic monoamine uptake by rat brain synaptosomes during aging. Effects of nootropic drugs.
- 1.Effects of the nootropic agents adafenoxate and meclofenoxate on brain biogenic monoamines in aged rats.
- 2.Changes in brain biogenic monoamines induced by the nootropic drugs adafenoxate and meclofenoxate and by citicholine (experiments on rats).
- 3.Comparative studies on the effects of the nootropic drugs adafenoxate, meclofenoxate and piracetam, and of citicholine on scopolamine-impaired memory, exploratory behavior and physical capabilities (experiments on rats and mice).
- 4.Effects of the nootropic agents adafenoxate, meclofenoxate and the acetylcholine precursor citicholine on the brain muscarinic receptors (experiments on rats).
- 5.Biogenic monoamine uptake by rat brain synaptosomes during aging. Effects of nootropic drugs.
- 6.Comparative studies on the effects of the nootropic drug adafenoxate and of the cerebral vasodilator flunarizine on arterial smooth muscles.
- 7.In vitro and in vivo effect of the nootropic agent adafenoxate on the 5-HT1 sites in different rat brain structures.
- 8.A study of nootropic drugs for anti-anxiety action.
8 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
How is it different from centrophenoxine?
Centrophenoxine (meclofenoxate) carries DMAE on a chlorophenoxyacetic acid; adafenoxate carries DMAE on a bulky adamantane group instead. In rodent studies the two behave similarly, with adafenoxate looking like a somewhat stronger monoamine-uptake inhibitor.
Is there human data?
Essentially none. The evidence base is a small set of Bulgarian animal studies from the 1980s and 1990s, so it is best treated as a research compound rather than a proven nootropic.
What does DMAE have to do with it?
DMAE is a choline relative connected to acetylcholine signaling and to keeping neuronal membranes healthy. These carrier esters are a way to deliver DMAE, which is thought to underlie part of the cholinergic and antioxidant story.
Would it help memory?
In rats it blunted scopolamine-induced amnesia, a classic anti-amnestic signal, but that has never been confirmed in people, so any memory benefit in humans is unproven.
Limitations of the evidence
- No human safety data
Notes and cautions
- Possible cholinergic overstimulation if overdone (inferred from the class)
- Caution alongside serotonergic or catecholaminergic drugs
- Research-chemical purity varies by source